Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Recent & Breaking News (NYSE:BMY)

Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis

Business Wire February 17, 2022

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma

Business Wire February 17, 2022

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy

Business Wire February 16, 2022

Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes

Business Wire February 15, 2022

Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion

Business Wire February 15, 2022

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Business Wire February 14, 2022

Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements

Business Wire February 9, 2022

Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.

Business Wire February 8, 2022

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021

Business Wire February 4, 2022

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B

Business Wire January 28, 2022

BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors

PR Newswire January 10, 2022

Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan's 40th Annual Healthcare Conference

Business Wire January 10, 2022

Bristol Myers Squibb to Present at J.P. Morgan's 40th Annual Healthcare Conference

Business Wire January 4, 2022

Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022

Business Wire December 17, 2021

U.S. Food and Drug Administration Approves Orencia® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)...

Business Wire December 15, 2021

Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization

Business Wire December 13, 2021

Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results

Business Wire December 11, 2021

BRISTOL MYERS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Bristol-Myers Squibb Company - BMY

Business Wire December 3, 2021

U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia

Business Wire December 3, 2021

CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY

PR Newswire December 1, 2021